Extracellular Vesicles (Exosomes) & Cardiovascular Disease - Single Course
.5 CME CREDITS – $50.00
Lecture begins with a detailed review of the current literature regarding exosomes and the Cardiovascular system. Then switch gears and discuss how exosomes can be used in your clinical practice. (1) The therapeutic and diagnostic role of exosomes in cardiovascular diseases will be discussed. This will include how exosomes and exosomal miRNAs are involved in cardiovascular protection and repair. Review of the bioactive molecules in exosomes and the various forms of miRNA and their roles in CVD. Exosomes and atherosclerosis, heart failure, cardiac regeneration, cardiomyopathy, their roles as functional CVD biomarkers and in gene therapy. Potential application of exosomes in drug delivery. Understanding the Paracrine Effects Exerted by Exosomes Secreted from Cardiac Cells in Cardiovascular Disease. The potential challenges and future perspectives in the use of exosomes for clinical cardiac applications. Combination therapies using exosomes and peptides in various cardiovascular conditions such as acute coronary syndromes, chronic coronary artery disease, hypertensive cardiovascular disease and congestive heart failure will also be reviewed. (2) I will review a turnkey solution to assist the cardiologist/health care provider in utilizing the technology of Exosomes in their office based medical practice to treat both acute and chronic cardiovascular conditions such as ischemic heart disease, peripheral vascular disease and hypertension. This will include a patient data management tool for your health care environment using a cloud-based system that allows patient data security via HIPAA compliant server, which may be customized to your facility’s unique clinical setting. This solution affords the opportunity to deliver regenerative care using FDA compliant and safe cellular based options to treat unmet patient needs, thus legitimizing regenerative therapies for your clinical practice.
*COMPLIANCE DISCLOSURE: AMMG has made every effort to have all lectures and statements made regarding Extracellular Vesicles comply with all FDA and State and Local laws. This is a science and knowledge based course, and Extracellular Vesicles is a new and potentially changing area of medicine. Currently Extracellular Vesicles can only be used in conjunction with an IRB with a FWA plus and IND/BLA, meaning FDA approval for a phase 1 clinical trial must be granted. We encourage you to frequently check for new policies, laws and rules which may apply to your practice and to strictly adhere to all laws which apply.
CME
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians / Nurses / Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Age Management Medicine Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM for physicians and 8.00 contact hours for nurses and 8.00 of knowledge/ -based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives – After attending this program you should be able to:
- Learn and understand the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
- Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
- Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed in the program book and have disclosed they have no relevant financial relationships.
Ian White, Ph.D.
Chief Scientific Officer, IMAC Regeneration Centers, Miami, FL
Chairman of the Scientific Committee, American Academy of Stem Cell Physicians
President, BioFirma, LLC
FACULTY DISCLOSURE:
IMAC Regeneration Centers: Scientific/Medical Advisory Board Member
Kathy O’Neil Smith, M.D.
Private Internal, Integrative and Regenerative Medicine Practice, Newton, MA
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed
George Shapiro, M.D.
Adjunct Assistant Professor Clinical Medicine, New York Medical College, Valhalla, NY
Founding Partner, Cenegenics, New York City
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE:
Organicell:Scientific/Meical Advisory Board Member, Organicell Stockholder, Cellularity: Scientific / Medical Advisory Board Member
Marvin Sponaugle, M.D.
Founder & President, North Pinellas Anesthesia, Oldsmar, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed
Paul Thompson, M.D.
Private Practice, Fort Worth, TX
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed
Daniel Sperling, M.D.
Medical Director & Chief of Interventional Uroradiology, Sperling Prostate Center, Florida & New York
Medical Director, Sperling Medical Group, Florida
Medical Director, Sperling Neurosurgery Associates, Florida
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed
Jeffrey Weiss, M.D.
Staff, Department of Surgery, North Broward Medical Center, Pompano Beach, FL
Board of Directors & Staff, Park Creek Surgery Center, Coconut Creek, FL
Staff, Al Zahra Hospital, Al Barsha, Dubai, U.A.E.
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed
Edwin Lee, M.D.
Assistant Professor of Internal Medicine, University of Central Florida, College of Medicine, Orlando, FL
Founder, Institute for Hormonal Balance, Orlando, FL
Member, AMMG Conference Planning Committee
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed
Rebecca Murray, APRN, FNP-BC, CDE
Endocrine Nurse Practitioner, Institute for Hormonal Balance, Orlando, FL
Medical Director, Ward-Murray HealthCare Consulting, Groton, CT
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed
Michale “Mickey” Barber, M.D.
CEO, CMO, Better Life Carolinas, Charleston, SC
FACULTY DISCLOSURE
No Relevant Financial Interest in any Products or Services to be discussed
William Kapp III, M.D., MS, FAAOS
Founder, Chairman/CEO, Longevity Bioimaging/Landmark Hospitals, Naples, FL
FACULTY DISCLOSURE:
No Relevant Financial Interest in any Products or Services to be discussed
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Release Date: January 15, 2020
Expiration Date: December 31, 2021
Learning Objectives:
- Explain the evidence-based science behind the use of Exosomes as an adjunct to an Age Management Medicine practice in the areas of biomarkers, ways of treating disease and use of targeted delivery vehicles for therapeutic molecules.
- Learn essential scientific information for the use of Exosomes in Age Management Medicine and how to clinically apply this knowledge to individualized treatment plans to improve outcomes.
- Understand how Exosomes can be applied clinically to various areas such as cardiac health, cancer, retinal and optic nerve conditions and gastrointestinal diseases.
SPECIAL OFFER
This course is part of the Exosomes: The Next Generation of Biologic Medicine bundle.
Purchase the complete series and save!
COURSE MENU
ACCOUNT MENU
NEED HELP?
Contact onlinecme@agemed.org
FACULTY
- Adjunct Assistant Professor Clinical Medicine, New York Medical College, Valhalla, NY
- Founding Partner, Cenegenics, New York City
- Member, AMMG Conference Planning Committee
George Shapiro, M.D.
Dr. Shapiro has been a practicing physician for 30 years, specializing in Internal Medicine, Cardiovascular Disease and Age Management Medicine. His career in medicine began in 1988 when he graduated from New York Medical College. An internship and residency then followed at Albert Einstein College of Medicine, after which Dr. Shapiro completed a fellowship at Columbia University College of Physicians and Surgeons in 1994, focusing on Cardiovascular Disease Management, including Congestive Heart Failure and Heart Transplantation. Dr. Shapiro was the recipient of the 10th Annual Alan P. Mintz, M.D. Award for Clinical Excellence in Age Management Medicine, as he has become known nationwide as an expert in age management medicine, and leads one of the most prominent age management practices in the country as president of Cenegenics New York City. Always challenged by the need for innovative medicine, Dr. Shapiro has patented medical devices as well as explored and innovated new medical protocols. He has long been known as one of New York’s foremost cardiologists, specializing in regenerative medicine and improving longevity, including the genomics of cardiovascular disease and congestive heart failure. Affiliated with New York Presbyterian Hospital and an Adjunct Assistant Clinical Professor in Clinical Medicine at New York Medical College, Dr. Shapiro is active in 13 medical societies, has been a speaker for the Age Management Medicine Group (AMMG) group for many years, and is a long-standing member of the AMMG Conference Planning Committee. Dr. Shapiro was named a 2017 Top Doctor in New York City.